Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($68.36); post-transaction worth based connected trade-date adjacent terms arsenic per SEC Form 4 filing.

• How does this merchantability comparison to Whitfield's anterior insider transactions astatine Tarsus Pharmaceuticals?
  The 12,274 shares sold exceeded the median insider merchantability of 9,835 shares implicit the past year, though it is successful enactment with her caller signifier of reducing holdings successful increments that bespeak disposable stock capacity.

• What proportionality of her wide presumption did Whitfield trim successful this transaction?
  This merchantability represented 25.95% of her nonstop holdings astatine the time, arsenic reported successful the filing, bringing her nonstop stock number from 47,302 to 35,028.

• Was this transaction connected to immoderate indirect entities oregon derivative exercises?
  All shares traded were held straight by Whitfield; determination were nary income from trusts, LLCs, oregon done derivative information exercises.

• What is the discourse for timing and marketplace pricing of these sales?
  The weighted mean merchantability terms was astir $68.36 per share, compared to a closing terms of $66.75 connected March 19, 2026; implicit the past year, Tarsus Pharmaceuticals shares had a full instrumentality of 22.48% arsenic of the transaction date.

* 1-year show is calculated utilizing March 19th, 2026 arsenic the notation date.

• Tarsus Pharmaceuticals develops and commercializes caller therapeutics for ophthalmic and different diseases, with its pb merchandise TP-03 targeting Demodex blepharitis and meibomian gland disease; further pipeline assets see TP-04 for rosacea and TP-05 for Lyme prophylaxis and malaria reduction.

• Tarsus targets ophthalmologists, dermatologists, and healthcare providers treating oculus and tegument diseases, with a absorption connected patients suffering from Demodex-related conditions and different underserved indications.

Tarsus Pharmaceuticals operates astatine the intersection of biotechnology and ophthalmology, focusing connected unmet aesculapian needs successful oculus attraction and related fields. The company's strategy centers connected advancing first-in-class therapeutics done late-stage objective improvement and commercialization. Its competitory borderline lies successful a differentiated pipeline addressing high-prevalence conditions with constricted attraction options, supported by a specialized commercialized infrastructure.